Abstract

The focus of this chapter is on antipsychotic agents—drugs also known as neuroleptics, antischizophrenic agents, and major tranquilizers (a misnomer). This pharmacological family has become a mainstay in the treatment of schizophrenia and other psychotic disorders as well as many nonpsychotic conditions . We deal primarily with the phenothiazines and related antipsychotic drugs but briefly discuss various experimental agents. The chapter also describes other approaches to treating psychoses and concludes by discussing future directions.

Keywords

Antipsychotic Drug Tardive Dyskinesia Neuroleptic Malignant Syndrome Antipsychotic Agent Antiparkinson Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    May P. R. A., Tuma A. H., Yale C., et al: Schizophrenia-a follow-up study of results of treatment. II. Hospital stay over two to five years. Arch Gen Psychiatry 33:431–506, 1976.CrossRefGoogle Scholar
  2. 2.
    Hogarty G. E., Goldberg S. C., Schooler N. R., et al: Drugs and social therapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 31:603–608, 1974.PubMedCrossRefGoogle Scholar
  3. 3.
    Epstein N. B., Vlok L. A.: Research on the results of psychotherapy: A summary of evidence. Am J Psychiatry 138:1027–1035, 1981.PubMedGoogle Scholar
  4. 4.
    Schooler N.R.: The efficacy of antipsychotic drugs and family therapies in the maintenance treatment of schizophrenia. J Clin Psychopharmacol 6:11S-19S, 1986.CrossRefGoogle Scholar
  5. 5.
    Gelenberg A. J.: The catatonic syndrome. Lancet 1:1339–1341, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Gelenberg A. J.: ECT: Controversies and consensus. Mass Gen Hosp Newslett Biol Ther Psychiatry 8:29–32, 1985.Google Scholar
  7. 7.
    Bartlett J., Bridges P., Kelly D.: Contemporary indications for psychosurgery. Br J Psychiatry 138:507–511, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Lipton M. A., Mailman R. B., Nemeroff C. B.: Vitamins, megavitamin therapy, and the nervous system, in Wurtman R. J., Wurtman J. J. (eds): Nutrition and the Brain, vol 3: Disorders of Eating and Nutrients in Treatment of Brain Diseases. New York, Raven Press, 1979, pp 183–264.Google Scholar
  9. 9.
    Gelenberg A. J.: Psychiatric disorders. In: Paige, D. M. (ed): Clinical Nutrition, ed 2. St. Louis: C V Mosby, 1988, pp 419–420.Google Scholar
  10. 10.
    Bassuk E. L.: The homelessness problem. Sci Am 251:40–45, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    McEvoy J. P.: The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 27:327–335, 1986.PubMedCrossRefGoogle Scholar
  12. 12.
    McEvoy J. P., Stiller R. L., Farr R.: Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol 6:133–138, 1986.PubMedCrossRefGoogle Scholar
  13. 13.
    Chouinard G., Jones B. D.: Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137:16–31, 1980.PubMedGoogle Scholar
  14. 14.
    Ross C. A.: Buspirone in the treatment of tardive dyskinesia. Med Hypoth 22:321–328, 1987.CrossRefGoogle Scholar
  15. 15.
    Cohen B. M., Lipinski J. F.: In vivo potencies of antipsychotic drugs in blocking alpha-1 noradrenergic and dopamine D-2 receptors: Implications for drug mechanisms of action. Life Sci 39:2571–2580, 1987.CrossRefGoogle Scholar
  16. 16.
    Gelenberg A. J.: Treating the outpatient schizophrenic. Postgrad Med 64:48–56, 1978.PubMedGoogle Scholar
  17. 17.
    Taylor W. J., Caviness M. H. D.: A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Irving, Texas, Abbott Laboratories, 1986, p. 467.Google Scholar
  18. 18.
    Ko G. N., Korpi E. R., Linnoila M.: On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics. J Clin Psychopharmacol 5:253–262, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Keepers G. A., Clappison V. J., Casey D. E.: Initial anticholinergic prophylaxis for neurolepticinduced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117, 1983.PubMedCrossRefGoogle Scholar
  20. 20.
    VanPutten T., Mutalipassi L. R., Malkin M. O.: Phenothiazine-induced decompensation. Arch Gen Psychiatry 30:102–106, 1974.PubMedCrossRefGoogle Scholar
  21. 21.
    Gelenberg A. J., Mandel M. R.: Catatonic reactions to high potency neuroleptic drugs. Arch Gen Psychiatry 34:947–950, 1977.PubMedCrossRefGoogle Scholar
  22. 22.
    Rifkin A., Quitkin F., Klein D. F.: Akinesia: A poorly recognized drug-induced extrapyramidal behavior disorder. Arch Gen Psychiatry 32:642–674, 1975.CrossRefGoogle Scholar
  23. 23.
    Wojcick J. D.: Antiparkinson drug use. Mass Gen Hosp Biol Ther Psychiatry Newslett 2:5–7, 1979.Google Scholar
  24. 24.
    Gelenberg A. J., VanPutten T., Lavori P., et al: Anticholinergic effects on memory: Benztropine versus amantadine. J Clin Psychopharmacol 9:180–185, 1989.PubMedCrossRefGoogle Scholar
  25. 25.
    Gelenberg A. J.: Amantadine in the treatment of benztropine-refractory neuroleptic-induced movement disorders. Curr Ther Res 23:375–380, 1978.Google Scholar
  26. 26.
    Smith J. M.: Abuse of the antiparkinson drugs: A review of the literature. J Clin Psychiatry 41:351–354, 1980.PubMedGoogle Scholar
  27. 27.
    Jeste D. V., Wyatt R. J.: Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry 138:297–309, 1981.PubMedCrossRefGoogle Scholar
  28. 28.
    Burke R. E., Fahn S., Jankovic J., et al: Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32:1335–1346, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    Morgenstern H., Glazer W. H., Niedzwiecki D., et al: The impact of neuroleptic medication on tardive dyskinesia: A meta-analysis of published studies. Am J Public Health 77:717–724, 1987.PubMedCrossRefGoogle Scholar
  30. 30.
    Wojcik J. D., Gelenberg A. J., Labrie R. A., et al: Prevalence of tardive dyskinesia in an outpatient population. Comp Psychiatry 21:370–380, 1980.CrossRefGoogle Scholar
  31. 31.
    Kane J. M., Woerner M., Borenstein M., et al: Integrating incidence and prevalence of tardive dyskinesia. Read before the IVth World Congress of Biological Psychiatry, Philadelphia, Sept 8–13, 1985.Google Scholar
  32. 32.
    Yassa R., Nair V., Dimitry R.: Prevalence of tardive dyskinesia. Acta Psychiatr Scand 73:629–633, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Gardos G., Cole J. O., Tarsy D.: Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 135:1321–1324, 1978.PubMedGoogle Scholar
  34. 34.
    Quitkin F., Rifkin A., Gochfeld L., et al: Tardive dyskinesia: Are first signs reversible? Am J Psychiatry 134:84–87, 1977.PubMedGoogle Scholar
  35. 35.
    Baldessarini R. J., Tarsy D.: Tardive dyskinesia, in Lipton M. A., DiMascio A., Killam K. F. (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 993–1004.Google Scholar
  36. 36.
    Casey D. E., Povisen U. J., Meidahl B., et al: Neuroleptic-induced tardive dyskinesia and parkinsonism: Changes during several years of continuing treatment. Psychopharmacol Bull 8(22):250–253, 1986.Google Scholar
  37. 37.
    Yagi G., Itoh H.: A ten-year follow-up study of tardive dyskinesia—with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med 34:211–219, 1985.PubMedCrossRefGoogle Scholar
  38. 38.
    Gelenberg A. J., Dorer D., Wojcik J., et al: A crossover study of lecithin for tardive dyskinesia. J Clin Psychiatry 51:149–153, 1990.PubMedGoogle Scholar
  39. 39.
    Caroff S. N.: The neuroleptic malignant syndrome. J Clin Psychiatry 41:79–83, 1980.PubMedGoogle Scholar
  40. 40.
    Gelenberg A. J., Bellinghausen B., Wojcik J. D., et al: A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 145:517–518, 1988.PubMedGoogle Scholar
  41. 41.
    Shalev A., Munitz H.: The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatrica Scand 73:337–347, 1986.CrossRefGoogle Scholar
  42. 42.
    Levinson D. F., Simpson G. M.: Neuroleptic-induced extrapyramidal symptoms with fever: Heterogeneity of the “neuroleptic malignant syndrome.” Arch Gen Psychiatry 43:839–848, 1986.PubMedCrossRefGoogle Scholar
  43. 43.
    Gelenberg A. J., Bellinghausen B., Wojcik J. D., et al: Patients with NMS histories: What happens when they are rehospitalized? J Clin Psychiatry 50:178–180, 1989.PubMedGoogle Scholar
  44. 44.
    Baldessarini R. J., Gelenberg A. J.: Using physostigmine safely. Am J Psychiatry 136:1608–1609, 1979.PubMedGoogle Scholar
  45. 45.
    Lieberman J. A., Johns C. A., Kane J. M., Rai K., Pisciotta A. V., Saltz B. L., Howard A.: Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 49:271–277, 1988.PubMedGoogle Scholar
  46. 46.
    Zarrabi M. H., Zucker S., Miller F., et al: Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 91:194–199, 1979.PubMedGoogle Scholar
  47. 47.
    Zucker S., Zarrabi H. M., Schuback W. H., et al. : Chlorpromazine-induced immunopathy: Progressive increase in serum IgM. Medicine 69:92–100, 1990.PubMedGoogle Scholar
  48. 48.
    Gelenberg A. J.: Psychotropic drugs during pregnancy and the perinatal period. Mass Gen Hosp Biol Ther Psychiatry Newslett 2:41–42, 1979.Google Scholar
  49. 49.
    Chouinard G., Jones B. D.: Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137:16–21, 1980.PubMedGoogle Scholar
  50. 50.
    Rivera-Calimlim L., Castaneda L., Lasagna L. : Effect of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 14:978–986, 1973.PubMedGoogle Scholar
  51. 51.
    Dysken M. W., Javaid J. I., Chang S. S., et al: Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73:205–210, 1981.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohen W. J., Cohen N. H.: Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 230:1283–1287, 1974.PubMedCrossRefGoogle Scholar
  53. 53.
    Spring G. K.: Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiatry 40:135–138, 1979.PubMedGoogle Scholar
  54. 54.
    Gelenberg A. J.: Is it safe to co-prescribe lithium with a neuroleptic? Mass Gen Hosp Biol Ther Psychiatry Newslett 2:13, 1979.Google Scholar
  55. 55.
    Rivera-Calimlim L., Kerzner B., Karch F. E.: Effect of lithium on plasma chlorpromazine level. Clin Pharmacol Ther 23:451–455, 1978.PubMedGoogle Scholar
  56. 56.
    Gelenberg A. J.: Coffee, tea, and antipsychotic drugs revisited. Mass Gen Hosp Biol Ther Psychiatry Newslett 4:42–43, 1981.Google Scholar
  57. 57.
    Gelenberg A. J.: Psychiatric emergencies: The psychotic patient. Drug Ther May 1981 pp 25–36.Google Scholar
  58. 58.
    Granacher R. P. Jr: Management of the acutely psychotic patient. Read before the Symposium on Antipsychotic Drug Therapy: Current Concepts and Future Trends, Key Biscayne, Florida, March 28, 1986.Google Scholar
  59. 59.
    Marner S. R., Putten T., Mintz J., et al: Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 44:518–521, 1987.CrossRefGoogle Scholar
  60. 60.
    Kane J., Honigfeld G., Singer J., Meltzer H.: The Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison vs chlorpromazine/ benztropine. Arch Gen Psychiatry 45:789–796, 1988.PubMedCrossRefGoogle Scholar
  61. 61.
    Meltzer H. Y.: Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Letter to editor. Arch Gen Psychiatry 46:672, 1989.PubMedCrossRefGoogle Scholar
  62. 62.
    Lieberman J. A., Kane J. M., Johns C. A.: Clozapine: Guidelines for clinical management, J Clin Psychiatry 50:329–338, 1989.PubMedGoogle Scholar
  63. 63.
    Lader M.: Introduction to Psychopharmacology. Kalamazoo, Upjohn, 1980, p 30.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Alan J. Gelenberg
    • 1
  1. 1.Department of PsychiatryUniversity of Arizona Health Sciences CenterTucsonUSA

Personalised recommendations